Session » Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 736

A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 678

Additional Information from CT or MRI Imaging Can Increase Rheumatologists’ Consensus on Grading Sacroiliitis By Radiography: Results of the Trimage Project

9:00AM-11:00AM: Abstract Number: 707

Anti-TNF Drugs Are Not Associated with Increasead Risk of Hzv Infections in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry

9:00AM-11:00AM: Abstract Number: 715

Are Patients with Ankylosing Spondylitis Willing to Pay for Treatment with Infliximab?

9:00AM-11:00AM: Abstract Number: 691

ASAS Health Index for Patients with Spondyloarthritis: Translation into Spanish, Validation, Reliability and Construct Validity

9:00AM-11:00AM: Abstract Number: 675

Association Between Structural Lesions in the Sacroiliac Joints and Spinal Inflammatory Lesions in Patients with Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 681

Can Bridging Syndesmophytes Independantly Affect Spinal Mobility?

9:00AM-11:00AM: Abstract Number: 730

Clinical and Quality of Life Improvements Observed with Golimumab and Infliximab in a Large Real-Life Ankylosing Spondylitis Population

9:00AM-11:00AM: Abstract Number: 726

Comparison of Infliximab Immunogenicity in Inflammatory Arthritis Versus Inflammatory Bowel Disease Patients in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 728

Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist

9:00AM-11:00AM: Abstract Number: 686

Development and Evaluation of the Combined Ankylosing Spondylitis Spine Score (CASSS) for the Assessment of Spinal Radiographic Outcome

9:00AM-11:00AM: Abstract Number: 680

Development and Preliminary Validation of the Computed Tomography Sacroiliac Structural Score for Assessment of Structural Lesions in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 709

Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study

9:00AM-11:00AM: Abstract Number: 708

Development of Spondyloarthritis-Features in Patients with Chronic Back Pain over a One-Year Course: Data from the Spondyloarthritis Caught Early (SPACE)-Cohort

9:00AM-11:00AM: Abstract Number: 694

Diagnostic Delay Leads to Worse Response to Treatment

9:00AM-11:00AM: Abstract Number: 679

Diagnostic Value of MR Enterography As a Complementary Intervention to Colonoscopy in Axial Spondylarthritis Patients with Chronic Non-Bloody Diarrhea

9:00AM-11:00AM: Abstract Number: 724

Diminished Spinal Radiographic Progression during Long-Term Treatment with TNF-α Inhibitors in Ankylosing Spondylitis Patients at Risk of Poor Radiographic Outcome

9:00AM-11:00AM: Abstract Number: 697

Does Axial Spondyloarthritis Phenotype Correlate with Imaging Morphotype?

9:00AM-11:00AM: Abstract Number: 704

Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?

9:00AM-11:00AM: Abstract Number: 729

Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?

9:00AM-11:00AM: Abstract Number: 727

Effects of Nsaids on Disease Activity in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 692

Efficacy and Safety of Biological Therapy and Target Synthetic Dmards: A Systematic Literature Review Informing the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 733

Efficacy and Safety of Non-Biological Therapy (Non-Biological Drugs and Non-Pharmacological Interventions): A Systematic Literature Review for the 2016 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 712

Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status

9:00AM-11:00AM: Abstract Number: 714

Functional Relevance of Structural Damage in the Sacroiliac Joints in Patients with Axial Spondyloarthritis – Results from the German Spondyloarthritis Inception Cohort

9:00AM-11:00AM: Abstract Number: 731

High Prevalence of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 723

Hip Disease Treatment and Progression in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 722

Impact of Aerobic Fitness on Axial Spondyloarthritis Activity: Systematic Review and Meta-Analysis of Controlled Studies

9:00AM-11:00AM: Abstract Number: 720

Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World

9:00AM-11:00AM: Abstract Number: 735

Impact of Time Since Diagnosis, Age, and Number of Prior Non-Steroidal Anti-Inflammatory Drugs on Response to Adalimumab (HUMIRA) in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 699

In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 701

In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity

9:00AM-11:00AM: Abstract Number: 700

Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications

9:00AM-11:00AM: Abstract Number: 690

Increase in Serum Leptin Levels Is Associated with Radiographic Progression of Male Patients with Ankylosing Spondylitis: A 2-Year Longitudinal Study

9:00AM-11:00AM: Abstract Number: 705

Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts

9:00AM-11:00AM: Abstract Number: 734

Lateral Spine BMD Measurement and Trabecular Bone Score Can Represent a Bone Loss in Patients with Advanced Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 725

Long-Term Anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in the Sacroiliac Joints in Patients with Non-Radiographic Axial Spa: Six-Year Results of the Esther Trial

9:00AM-11:00AM: Abstract Number: 732

Long-Term Effect of TNF Inhibitors on Radiographic Progression in Ankylosing Spondylitis Is Associated with Syndesmophytes at Baseline and Time-Averaged CRP Levels

9:00AM-11:00AM: Abstract Number: 677

Low Functional Relevance of Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 717

NSAID Use and Functional Impairment in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 685

Paradoxical Psoriasis Secondary to Anti-Tnfa Agents in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 710

Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of the Open-Label Extension of a Randomized, Double-Blind Study

9:00AM-11:00AM: Abstract Number: 703

Performance of a New Spinal Mobility Index for Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 698

Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 706

Performance of the ASAS Classification Criteria for Axial and Peripheral Spondyloarthritis – a Systematic Literature Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 713

Predictors of Treatment Retention Among Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Remicade® (Infliximab) for Long-Term in Canadian Real-World

9:00AM-11:00AM: Abstract Number: 719

Prevalence and Incidence of Comorbidities in Patients with Ankylosing Spondylitis Versus General Population

9:00AM-11:00AM: Abstract Number: 716

Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors

9:00AM-11:00AM: Abstract Number: 718

Radiographic Progression of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 689

Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 683

Risk Factors of Uveitis in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 687

Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 721

Safety and Efficacy of Switching from Originator to CT-P13 Infliximab Biosimilar in Patients Affected By Spondyloarthritis. a 6-Month Observational Study

9:00AM-11:00AM: Abstract Number: 695

Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial

9:00AM-11:00AM: Abstract Number: 696

Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab

9:00AM-11:00AM: Abstract Number: 688

Spondyloarthritis Research Consortium of Canada (SPARCC) Baseline MRI SI Joint Score ≥2 Better Predicts Response to Golimumab Than Does Assessment of Spondyloarthritis International Society (ASAS) MRI Positivity in Nonradiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 684

Subchondral Bone Sclerosis on Computed Tomography – Does It Have Any Value in the Diagnosis of Inflammatory Sacroiliitis or Is It a Non-Specific Finding?

9:00AM-11:00AM: Abstract Number: 676

Syndesmophytes in the Thoracic Spine in Ankylosing Spondylitis As Detected By Computed Tomography and Association with Lumbar Radiographic Involvement

9:00AM-11:00AM: Abstract Number: 711

The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting

9:00AM-11:00AM: Abstract Number: 693

The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis

9:00AM-11:00AM: Abstract Number: 702

Treatment with Golimumab or Infliximab Reduces Health Resource Utilization and Increases Work Productivity in Patients with Ankylosing Spondylitis in a Large, Prospective Real-Life Cohort

9:00AM-11:00AM: Abstract Number: 682

Which Is the Most Reliable Imaging Method for Detection of Structural Changes in the Sacroiliac Joints of Patients with Ankylosing Spondylitis? a Cross-Sectional Study Comparing MRI, CT and Conventional Radiographs

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].